Clinical Background

NexoBrid™ has been investigated in over 550 patients in Phase II and Phase III clinical studies by more than 100 leading burn specialists from 15 countries and 4 continents.

NexoBrid efficacy was demonstrated in a randomized, multi-center, open-label, controlled, confirmatory, Phase III trial conducted in 13 countries and involving 182 patients**, who were treated with either NexoBrid™ (75 patinets, 163 deep burns) or Standard of Care (SOC; 81 patients, 180 deep burns). The study was successfully completed after a pre-planned interim analysis that successfully demonstrated NexoBrid™ superiority in both co-primary end points and the ability of NexoBrid™ to Debride and Protect.

**  overall 156 randomised patients and 26 NexoBrid training patients (the 1st patient in each site).